Competing Interests of Authors: Full Disclosure

Sanofi and Regeneron Pharmaceuticals have received European Commission approval for their drug Dupixent (dupilumab) to treat chronic obstructive pulmonary disease (COPD), a significant milestone for the companies and a potential…

You can read the full story here: Competing Interests of Authors: Full Disclosure .

Source link

Leave a Comment